BR112021025701A2 - Isoxazoline parasiticide formulations and methods to treat blepharitis - Google Patents

Isoxazoline parasiticide formulations and methods to treat blepharitis

Info

Publication number
BR112021025701A2
BR112021025701A2 BR112021025701A BR112021025701A BR112021025701A2 BR 112021025701 A2 BR112021025701 A2 BR 112021025701A2 BR 112021025701 A BR112021025701 A BR 112021025701A BR 112021025701 A BR112021025701 A BR 112021025701A BR 112021025701 A2 BR112021025701 A2 BR 112021025701A2
Authority
BR
Brazil
Prior art keywords
methods
blepharitis
isoxazoline
isoxazoline parasiticide
ophthalmic
Prior art date
Application number
BR112021025701A
Other languages
Portuguese (pt)
Inventor
Robert Azamian Bobak
Michael Ackermann Douglas
Joseph Vehige
Shawn Hickok
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Publication of BR112021025701A2 publication Critical patent/BR112021025701A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Abstract

formulações e métodos de parasiticida de isoxazolina para tratar blefarite. são revelados na presente invenção métodos para tratar ou prevenir condições oftálmicas e dermatológicas em um paciente, incluindo condições da superfície ocular, como blefarite. os métodos podem incluir a administração tópica diretamente a uma superfície ocular de um ou mais olhos de um paciente em necessidade de tratamento de uma quantidade eficaz de um parasiticida de isoxazolina, parasiticida de formamidina ou outro ingrediente ativo, formulado em uma composição oftálmica, a composição oftálmica adicionalmente compreendendo um veículo farmaceuticamente aceitável. as composições também são reveladas.isoxazoline parasiticide formulations and methods for treating blepharitis. Disclosed in the present invention are methods of treating or preventing ophthalmic and dermatological conditions in a patient, including ocular surface conditions such as blepharitis. the methods may include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment an effective amount of an isoxazoline parasiticide, formamidine parasiticide or other active ingredient, formulated in an ophthalmic composition, the composition ophthalmic solution further comprising a pharmaceutically acceptable carrier. the compositions are also revealed.

BR112021025701A 2019-06-19 2020-06-19 Isoxazoline parasiticide formulations and methods to treat blepharitis BR112021025701A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863822P 2019-06-19 2019-06-19
US202063029689P 2020-05-25 2020-05-25
PCT/US2020/038758 WO2020257663A1 (en) 2019-06-19 2020-06-19 Isoxazoline parasiticide formulations and methods for treating blepharitis

Publications (1)

Publication Number Publication Date
BR112021025701A2 true BR112021025701A2 (en) 2022-03-03

Family

ID=74040459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025701A BR112021025701A2 (en) 2019-06-19 2020-06-19 Isoxazoline parasiticide formulations and methods to treat blepharitis

Country Status (10)

Country Link
EP (1) EP3986377A4 (en)
JP (1) JP2022537389A (en)
KR (1) KR20220053550A (en)
CN (1) CN114269324A (en)
AU (1) AU2020295570A1 (en)
BR (1) BR112021025701A2 (en)
CA (1) CA3144264A1 (en)
IL (1) IL289109A (en)
MX (1) MX2021016055A (en)
WO (1) WO2020257663A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220323472A1 (en) * 2021-03-30 2022-10-13 Frank Anthony SPALLITTA Anti-parasitic compounds for the treatment and prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119174A1 (en) * 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2891460B1 (en) * 2005-09-30 2010-07-30 Galderma Sa USE OF AT LEAST ONE COMPOUND OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF OPHTHALMIC DISEASES DUE TO DEMODEX FOLLICULORUM.
US20090317503A1 (en) * 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
EP2557922A2 (en) * 2010-04-12 2013-02-20 Exosect Limited Control of arthropods in animal environments
WO2012107533A1 (en) * 2011-02-10 2012-08-16 Novartis Ag Isoxazoline derivatives for controlling invertebrate pests
CN110327468B (en) * 2013-12-20 2023-04-28 英特维特国际股份有限公司 Isoxazoline compositions and their use in preventing or treating parasite infestations in animals
WO2016022066A1 (en) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
RU2020122841A (en) * 2017-12-15 2022-01-18 Тарсус Фармасьютикалс, Инк. ISOXAZOLINE PARASITICIDAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEPHARITIS
CA3107590A1 (en) * 2018-07-27 2020-01-30 Aperta Biosciences, Llc Spinosyn formulations for treatment of demodex-induced ocular and facial conditions

Also Published As

Publication number Publication date
MX2021016055A (en) 2022-04-20
CN114269324A (en) 2022-04-01
CA3144264A1 (en) 2020-12-24
KR20220053550A (en) 2022-04-29
JP2022537389A (en) 2022-08-25
WO2020257663A1 (en) 2020-12-24
EP3986377A4 (en) 2023-07-19
EP3986377A1 (en) 2022-04-27
AU2020295570A1 (en) 2022-02-10
IL289109A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MX2020012595A (en) Topical pharmaceutical compositions.
BR112017026159A2 (en) heterocyclic erk1 and erk2 inhibitors and their use in cancer treatment
BR112014028633A8 (en) amd treatment using aav sflt-1
MX2020010907A (en) Enhancement of delivery of lipophilic active agents across the blood-brain barrier and methods for treating central nervous system disorders.
CR20210201A (en) New anthelmintic compounds
BR112015007778A2 (en) vegf neutralizing prodrugs for the treatment of eye conditions
BR112012018500A2 (en) some quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof
MX2019003397A (en) Methods of treating mitochondrial and metabolic disorders.
CO2019010078A2 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods for treating ire1-related diseases and disorders
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
BR112015021334A2 (en) Ocular formulations for drug delivery to the posterior segment of the eye
BR112021025764A2 (en) Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof
EA202191684A1 (en) DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA
CO2021000229A2 (en) Pyrazole and imidazole compounds for the inhibition of yl-17 and rorgamma
BR112019007863A2 (en) innovative naphthyridinone derivatives and their use in the treatment of arrhythmia
BR112013032911A2 (en) leukotoxin e / d as a new anti-inflammatory and microbicidal agent
BR112021025701A2 (en) Isoxazoline parasiticide formulations and methods to treat blepharitis
BR112018072647A2 (en) ophthalmic compositions
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
AU2020299145A8 (en) Compositions and methods for treating eye diseases
MX2018011539A (en) Treatment of skin conditions and diseases associated with microbial biofilms.
BR112015009504A2 (en) rock inhibitors
BR112023002089A2 (en) 6- SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADATORS